The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
Open accessAbstract
The predictive value of KRAS mutation in metastatic colorectal cancer (MCRC) patients treated with cetuximab plus chemotherapy has recently been suggested. In our study, 59 patients with a chemotherapy-refractory MCRC treated with cetuximab plus chemotherapy were included and clinical response was evaluated according to response evaluation criteria in solid tumours (RECIST). Tumours were screened for KRAS mutations using first direct sequencing, then two sensitive methods based on SNaPshot and PCR-ligase chain reaction (LCR) assays. Clinical response was evaluated according to gene mutations using the Fisher exact test. Times to progression (TTP) were calculated using the Kaplan-Meier method and compared with log-rank test. A KRAS mutation was detected in 22 out of 59 tumours and, in six cases, was missed by sequencing analysis but detected using the SNaPshot and PCR-LCR assays. Remarkably, no KRAS mutation was found in the 12 patients with clinical response. KRAS mutation was associated with disease progression (P=0.0005) and TTP was significantly decreased in mutated KRAS patients (3 vs 5.5 months, P=0.015). Our study confirms that KRAS mutation is highly predictive of a non-response to cetuximab plus chemotherapy in MCRC and highlights the need to use sensitive molecular methods, such as SNaPshot or PCR-LCR assays, to ensure an efficient mutation detection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“as major determinants of primary resistance to cetuximab or panitumumab [17, 27-29].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Kabbinavar, F. F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Liebérman, G., Griffing, S., & Bergsland, E. K. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,711
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,080
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Systemic Therapy for Colorectal Cancer
Varghese, A. M. (2019) · DeckerMed CGSO Case-Based Reviews · doi:10.2310/cgso.16189 · Cited by 883
LigAmp for sensitive detection of single-nucleotide differences
Shi, C., Eshleman, S. H., Jones, D. C., Fukushima, N., Li, H., Parker, A. R., Yeo, C. J., Hruban, R. H., Goggins, M., & Eshleman, J. R. (2004) · Nature Methods · doi:10.1038/nmeth713 · Cited by 127
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 734
Oncogenic mutations as predictive factors in colorectal cancer
Lièvre, A., Blons, H., & Laurent-Puig, P. (2010) · Oncogene · doi:10.1038/onc.2010.89 · Cited by 117
Gallagher, D. J., Konner, J. A., Bell-McGuinn, K. M., Bhatia, J., Sabbatini, P. J., Aghajanian, C. A., Offit, K., Barakat, R. R., Spriggs, D. R., & Kauff, N. D. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq577 · Cited by 118
Lurje, G., Nagashima, F., Zhang, W., Yang, D., Chang, H. M., Gordon, M. A., El-Khoueiry, A. B., Husain, H., Wilson, P. M., Ladner, R. D., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5165 · Cited by 115
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial
Ocvirk, J. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i25.3133 · Cited by 114
Cremolini, C., Antoniotti, C., Lonardi, S., Aprile, G., Bergamo, F., Masi, G., Grande, R., Tonini, G., Mescoli, C., Cardellino, G. G., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5314 · Cited by 116
Targeted therapy for hepatocellular carcinoma
Spangenberg, H. C., Thimme, R., & Blum, H. E. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.86 · Cited by 112
Tabernero, J., Cervantes, A., Rivera, F., Martinelli, E., Rojo, F., von Heydebreck, A., Macarulla, T., Rodriguez-Braun, E., Eugenia Vega-Villegas, M., Senger, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6043 · Cited by 110
Hecht, J. R., Mitchell, E., Neubauer, M. A., Burris, H. A., Swanson, P., Lopez, T., Buchanan, G., Reiner, M., Gansert, J., & Berlin, J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2017 · Cited by 110
Tougeron, D., Lecomte, T., Pagès, J., Villalva, C., Collin, C., Ferru, A., Tourani, J. M., Silvain, C., Levillain, P., & Karayan, L. (2013) · Annals of Oncology · doi:10.1093/annonc/mds620 · Cited by 115
KRAS Mutation Testing in Colorectal Cancer
Plesec, T. P., & Hunt, J. L. (2009) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181a9d4ed · Cited by 108
Baker, J. B., Dutta, D., Watson, D., Maddala, T., Munneke, B., Shak, S., Rowinsky, E. K., Xu, L.-A., Harbison, C. T., Clark, E. A., et al. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606054 · Cited by 110
Azzopardi, N., Lecomte, T., Ternant, D., Boisdron-Celle, M., Piller, F., Morel, A., Gouilleux‐Gruart, V., Desvignes, C., Watier, H., Gamelin, E. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1081 · Cited by 110
Vecchione, L., Jacobs, B., Normanno, N., Ciardiello, F., & Tejpar, S. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.08.021 · Cited by 109
Self-Assembly of Lithographically Patterned Nanoparticles
Cho, J., & Gracias, D. H. (2009) · Nano Letters · doi:10.1021/nl9022176 · Cited by 108
Molecular Alterations and Biomarkers in Colorectal Cancer
Grady, W. M., & Pritchard, C. C. (2013) · Toxicologic Pathology · doi:10.1177/0192623313505155 · Cited by 112
Yen, L.-C., Yeh, Y., Chen, C., Wang, H., Tsai, H., Lu, C.-Y., Chang, Y., Chu, K., Lin, S., & Wang, J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3179 · Cited by 102
MicroRNA profiling differentiates colorectal cancer according to KRAS status
Mosakhani, N., Sarhadi, V. K., Borze, I., Karjalainen‐Lindsberg, M., Sundström, J. T. T., Ristamäki, R., Osterlund, P. J., & Knuutila, S. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20925 · Cited by 103
Shi, Q., de Gramont, A., Grothey, A., Zalcberg, J. R., Chibaudel, B., Schmoll, H., Seymour, M., Adams, R., Saltz, L. B., Goldberg, R. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.5887 · Cited by 100
Sood, A., McClain, D., Maitra, R., Basu-Mallick, A., Seetharam, R. N., Kaubisch, A., Rajdev, L. N., Mariadason, J. M., Tanaka, K. E., & Goel, S. (2012) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.12.001 · Cited by 100
Frequency and Type of KRAS Mutations in Routine Diagnostic Analysis of Metastatic Colorectal Cancer
Neumann, J. H. L., Zeindl‐Eberhart, E., Kirchner, T., & Jung, A. (2009) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0029-1242277 · Cited by 98
Custodio, A., & Feliú, J. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.05.001 · Cited by 100
Biomarkers in precision therapy in colorectal cancer
Reimers, M. S., Zeestraten, E. C. M., Kuppen, P. J. K., Liefers, G., & van de Velde, C. J. �. (2013) · Gastroenterology report · doi:10.1093/gastro/got022 · Cited by 99
Debucquoy, A., Haustermans, K. M., Daemen, A., Aydın, S., Libbrecht, L. J., Gevaert, O., Moor, B. D., Tejpar, S., McBride, W. H., PENNINCKX, F. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5033 · Cited by 96
Yoon, J., Koo, K.-H., & Choi, K.-Y. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3058 · Cited by 92
Qiu, L., Mao, C., Zhang, J., Zhu, X.-D., Liao, R.-Y., Xue, K., Li, J., & Chen, Q. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.05.022 · Cited by 98
Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls
Lamy, A., Blanchard, F., Pessot, F. L., Sesboüé, R., Fiore, F. D., Bossut, J., Fiant, E., Frébourg, T., & Sabourin, J. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.60 · Cited by 93
Self-citationPancreatic cancer: from molecular pathogenesis to targeted therapy
Strimpakos, A. S., Saif, M. W., & Syrigos, K. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9134-y · Cited by 91
Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803
Ng, K., Ogino, S., Meyerhardt, J. A., Chan, J. A., Chan, A. T., Niedzwiecki, D., Hollis, D. R., Saltz, L. B., Mayer, R. J., Benson, A. B., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr307 · Cited by 93
Baas, J. M., Krens, L. L., Guchelaar, H.-J., Morreau, H., & Gelderblom, H. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0024 · Cited by 89
Ades, S., Kumar, S., Alam, M., Goodwin, A., Weckstein, D. J., Dugan, M., Ashikaga, T., Evans, M., Verschraegen, C. F., & Holmes, C. E. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12910 · Cited by 89
Bengala, C., Bettelli, S. R., Bertolini, F., Salvi, S., Chiara, S., Sonaglio, C., Losi, L., Bigiani, N., Sartori, G., Dealis, C., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn647 · Cited by 87
Yen, L.-C., Uen, Y., Wu, D., Lu, C.-Y., Yu, F., Wu, I., Lin, S., & Wang, J. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181bc9d96 · Cited by 89
Kirsten Ras* oncogene: Significance of its discovery in human cancer research
Tsuchida, N., Murugan, A. K., & Grieco, M. (2016) · Oncotarget · doi:10.18632/oncotarget.8773 · Cited by 94
Leto, S. M., & Trusolino, L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1161-2 · Cited by 87
KRAS Mutation Testing in Human Cancers: The Pathologist's Role in the Era of Personalized Medicine
Wang, H. L., Lopategui, J. R., Amin, M. B., & Patterson, S. D. (2010) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181c6962f · Cited by 90
Genomics and the History of Precision Oncology
Doroshow, D. B., & Doroshow, J. H. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.08.003 · Cited by 93
Mao, C., Liao, R.-Y., Qiu, L., Wang, X.-W., Ding, H., & Chen, Q. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0351-4 · Cited by 91
Precision medicine in colorectal cancer: the molecular profile alters treatment strategies
Tran, N. H., Cavalcante, L. L., Lubner, S. J., Mulkerin, D. L., LoConte, N. K., Clipson, L. J., Matkowskyj, K. A., & Deming, D. A. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015591952 · Cited by 85
Are RAS mutations predictive markers of resistance to standard chemotherapy?
Loriot, Y., Mordant, P., Deutsch, É., Olaussen, K. A., & Soria, J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.106 · Cited by 84
Chen, C.-C., Er, T., Liu, Y., Hwang, J., Barrio, M. J., Rodrigo, M., García-Toro, E., & Herreros‐Villanueva, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055793 · Cited by 85
oden-Gangloff, A., Fiore, F. D., Bibeau, F., Lamy, A., Bougeard, G., Charbonnier, F., Blanchard, F., Tougeron, D., Ychou, M., Boissière‐Michot, F., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605008 · Cited by 90
Self-citationWatanabe, T., Kobunai, T., Yamamoto, Y., Matsuda, K., Ishihara, S., Nozawa, K., Iinuma, H., Shibuya, H., & Eshima, K. (2011) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e31821d37a3 · Cited by 82
Assénat, E., Desseigne, F., Thézenas, S., Viret, F., Mineur, L., Kramar, A., Samalin, E., Portales, F., Bibeau, F., Crapez-Lopez, E., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0141 · Cited by 84
Stintzing, S., Kapaun, C., Laubender, R. P., Jung, A., Neumann, J. H. L., Modest, D. P., Giessen, C. A., Moosmann, N., Wollenberg, A., Kirchner, T., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27654 · Cited by 83
Tol, J., Dijkstra, J. R., Vink-Börger, M. E., Nagtegaal, I. D., Punt, C. J. A., van Krieken, J. H., & Ligtenberg, M. J. L. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00788.x · Cited by 81
Using Genome Sequence to Enable the Design of Medicines and Chemical Probes
Angelbello, A. J., Chen, J. L., Childs‐Disney, J. L., Zhang, P., Wang, Z.-F., & Disney, M. D. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00504 · Cited by 81
García‐Foncillas, J., Tabernero, J. M., Élez, E., Aranda, E., Benavides, M., Camps, C., Lewintre, E. J., López‐López, R., Muinelo‐Romay, L., Montagut, C. O., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0293-5 · Cited by 84
Resistance to EGF-R (erbB-1) and VEGF-R modulating agents
Dempke, W. C. M., & Heinemann, V. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.11.038 · Cited by 78
Mlčochová, J., Vychytilova‐Faltejskova, P., Ferracin, M., Zagatti, B., Radová, L., Svoboda, M., Němeček, R., John, S., Kišš, I., Vyzula, R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5735 · Cited by 79
RAS and BRAF in metastatic colorectal cancer management
Gong, J., Cho, M. T., & Fakih, M. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.06.12 · Cited by 84
Köhne, C., Hofheinz, R., Mineur, L., Letocha, H., Greil, R., Thaler, J., Fernebro, E., Gamelin, E. C., DeCosta, L., & Karthaus, M. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-1061-6 · Cited by 80
Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis
Petrelli, F., Borgonovo, K., Cabiddu, M., Ghilardi, M., & Barni, S. (2011) · International Journal of Colorectal Disease · doi:10.1007/s00384-011-1149-0 · Cited by 78
EGFR-Targeted Therapies in Lung Cancer: Predictors of Response and Toxicity
Heist, R. S., & Christiani, D. C. (2008) · Pharmacogenomics · doi:10.2217/14622416.10.1.59 · Cited by 81
Fakih, M., & Wong, R. (2010) · Current Oncology · doi:10.3747/co.v17is1.616 · Cited by 76
Spindler, K.-L. G., Pallisgaard, N., Rasmussen, A. A., Lindebjerg, J., Andersen, R. F., Crüger, D. G., & Jakobsen, A. K. M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn712 · Cited by 78
Determinants of RASistance to Anti–Epidermal Growth Factor Receptor Agents
Baselga, J. M., & Rosen, N. X. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.3700 · Cited by 76
Scartozzi, M., Mandolesi, A., Giampieri, R., Pierantoni, C., Loupakis, F., Zaniboni, A., Galizia, E., Giustini, L., Silva, R. R., Bisonni, R., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25193 · Cited by 74
Wang, J., Chen, B., Wang, Y., Tsai, Y.-T., Chen, W.-C., Chang, W., Hou, M., Wu, Y., & Chang, W.-C. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.08.017 · Cited by 73
Gonçalvès, A., Esteyriès, S., Taylor-Smedra, B., Lagarde, A., Ayadi, M., Monges, G. M., Bertucci, F., Esterni, B., Delpéro, J., Turrini, O., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-169 · Cited by 73
Diep, C. H., Muñoz, R. M., Choudhary, A. K., Hoff, D. D. V., & Han, H. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2214 · Cited by 74
Scartozzi, M., Bearzi, I., Mandolesi, A., Pierantoni, C., Loupakis, F., Zaniboni, A., Negri, F., Quadri, A., Zorzi, F., Galizia, E., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-303 · Cited by 72
Stefano, A. D., Carlomagno, C., Pepe, S., Bianco, R., & Placido, S. D. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1604-1 · Cited by 72
Scartozzi, M., Bearzi, I., Mandolesi, A., Giampieri, R., Faloppi, L., Galizia, G., Loupakis, F., Zaniboni, A., Zorzi, F., Biscotti, T., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.161 · Cited by 72
Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer
Fiore, F. D., Sesboüé, R., Michel, P., Sabourin, J., & Frébourg, T. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6606008 · Cited by 76
Self-citationNew Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer
Prenen, H., Tejpar, S., & Cutsem, E. V. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2029 · Cited by 72
Basavaraj, C., Sierra, P., Shivu, J., Melarkode, R., Monte, E., & Nair, P. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.7.12793 · Cited by 71
Role of targeted agents in metastatic colorectal cancer
Prenen, H., Vecchione, L., & Cutsem, E. V. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0281-x · Cited by 70
Adelstein, B., Dobbins, T., Harris, C. A., Marschner, I. C., & Ward, R. L. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.03.031 · Cited by 72
Su, X. Q., Lacouture, M. E., Jia, Y., & Wu, S. (2009) · Oncology · doi:10.1159/000229752 · Cited by 66
KRAS Mutation Testing in the Treatment of Metastatic Colorectal Cancer with Anti-EGFR Therapies
Soulières, D., Greer, W. L., Magliocco, A. M., Huntsman, D. D., Young, S. S., Tsao, M., & Kamel‐Reid, S. (2010) · Current Oncology · doi:10.3747/co.v17is1.614 · Cited by 66
Kim, T. W., Elme, A., Kusić, Z., Park, J. O., Udrea, A. A., Kim, S. Y., Ahn, J. B., Villalobos-Valencia, R., Krishnan, S., Bilic, A., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.309 · Cited by 67
Blank, P. R., Moch, H., Szucs, T. D., & Schwenkglenks, M. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2267 · Cited by 67
Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune Diseases
Pilzweger, C., & Holdenrieder, S. (2015) · Diagnostics · doi:10.3390/diagnostics5020219 · Cited by 67
EGFR and colon cancer: a clinical view
de Castro, J., Belda-Iniesta, C., Sáenz, E. C., Agudo, E. H., Batlle, J. F., & Barón, M. G. (2008) · Clinical & Translational Oncology · doi:10.1007/s12094-008-0147-3 · Cited by 68
Morgan, S. R., Whiteley, J. L., Donald, E. L., Smith, J. C., Eisenberg, M. T., Kallam, E., & Kam-Morgan, L. N. W. (2012) · Clinical Medicine Insights Pathology · doi:10.4137/cpath.s8798 · Cited by 63
Scartozzi, M., Mandolesi, A., Giampieri, R., Bittoni, A., Pierantoni, C., Zaniboni, A., Galizia, G., Giustini, L., Silva, R. R., Bisonni, R., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0119 · Cited by 63
Oh, B. Y., Lee, W. Y., Jung, S., Hong, H. K., Nam, D., Park, Y. A., Huh, J. W., Yun, S. H., Kim, H. C., Chun, H.-K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3863 · Cited by 62
Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy
Alves, S., Castro, L., Fernandes, M. S., Francisco, R., Castro, P. J. T. D., Priault, M., Chaves, S. R., Moyer, M. P., Oliveíra, C., Seruca, R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5021 · Cited by 64
Bianchini, D., Jayanth, A., Chua, Y. J., & Cunningham, D. (2008) · Clinical Colorectal Cancer · doi:10.3816/ccc.2008.n.005 · Cited by 62
Hecht, J. R., Douillard, J., Schwartzberg, L. S., Grothey, A., Kopetz, S., Rong, A., Oliner, K. S., & Sidhu, R. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.05.008 · Cited by 63
Clancy, C., Burke, J. P., & Coffey, J. C. (2013) · Surgical Oncology · doi:10.1016/j.suronc.2013.02.001 · Cited by 60
Circulating free tumor DNA and colorectal cancer
Lecomte, T., Cézé, N., Dorval, E. D., & Laurent‐Puig, P. (2010) · Gastroentérologie Clinique et Biologique · doi:10.1016/j.gcb.2009.04.015 · Cited by 59
Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer
Sánchez‐Muñoz, A., Gallego, E., de Luque, V., Perez‐Rivas, L. G., Vicioso, L., Ribelles, N., Lozano, J., & Alba, E. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-136 · Cited by 59
Improving Gemcitabine-Mediated Radiosensitization Using Molecularly Targeted Therapy: A Review
Morgan, M. A., Parsels, L. A., Maybaum, J., & Lawrence, T. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1032 · Cited by 59
Molecular Diagnostics of Colorectal Cancer
Bedeir, A., & Krasinskas, A. M. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0613-rair.1 · Cited by 59
Markers of resistance to anti-EGFR therapy in colorectal cancer.
Shaib, W. L., Mahajan, R., & El‐Rayes, B. F. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2013.029 · Cited by 61
Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer
Dahan, L., Norguet, E., Étienne-Grimaldi, M.-C., Formento, J., Gasmi, M., Nanni, I., Gaudart, J., Garcia, S., Ouafik, L., Seitz, J., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-496 · Cited by 58
Bringing Structural Implications and Deep Learning-Based Drug Identification for KRAS Mutants
Mehmood, A., Kaushik, A. C., Wang, Q., Li, C.-D., & Wei, D. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00488 · Cited by 57
Davidson, C. J., Zeringer, E., Champion, K. J., Gauthier, M. L., Wang, F., Boonyaratanakornkit, J., Jones, J. R., & Schreiber, E. H. (2012) · BioTechniques · doi:10.2144/000113913 · Cited by 56
Riely, G. J., & Ladanyi, M. (2008) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.080105 · Cited by 58
Circulating tumor cells in colorectal cancer patients
Torino, F., Bonmassar, E., Bonmassar, L., Vecchis, L. D., Barnabei, A., Zuppi, C., Capoluongo, E., & Aquino, A. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.12.007 · Cited by 57
Zhu, Z. (2007) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2007.00681.x · Cited by 60
Brodowicz, T., Ciuleanu, T., Radosavljevic, D. Z., Shacham‐Shmueli, E., Vrbanec, D., Plāte, S., Mršić-Krmpotić, Z., Dank, M., Purkalne, G., Messinger, D., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt116 · Cited by 57
Lièvre, A., Samalin, E., Mitry, E., Assénat, E., Gestin-Boyer, C., Lepère, C., Bachet, J., Portales, F., Vaillant, J.-N., Ychou, M., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-347 · Cited by 56
Samalin, E., Bouché, O., Thézenas, S., François, É., Adenis, A., Bennouna, J., Taı̈eb, J., Desseigne, F., Seitz, J. F., Conroy, T., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.813 · Cited by 55
Self-citationProgress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome
García‐Foncillas, J., & Díaz‐Rubio, E. (2010) · Clinical & Translational Oncology · doi:10.1007/s12094-010-0551-3 · Cited by 55
Zhao, J., Gong, L., Xie, C., Zhang, L., Su, H., Deng, X., & Wu, S. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.08.008 · Cited by 54
Levin-Sparenberg, E., Bylsma, L. C., Lowe, K. A., Sangaré, L. R., Fryzek, J. P., & Alexander, D. D. (2020) · Gastroenterology Research · doi:10.14740/gr1167 · Cited by 53
Hutchinson, R. A., Adams, R., McArt, D. G., Salto‐Tellez, M., Jasani, B., & Hamilton, P. W. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0531-z · Cited by 57
Predictive biomarkers for personalised anti-cancer drug use: Discovery to clinical implementation
Alymani, N. A., Smith, M. D., Williams, D. J., & Petty, R. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.01.001 · Cited by 53
Metadata
- Authors
- Di Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., Lamy, A., Galais, M. P., Bastit, L., Killian, A., Sesboüé, R., Tuech, J. J., Queuniet, A. M., Paillot, B., Sabourin, J. C., Michot, F., Michel, P., & Frebourg, T.
- Affiliations
- Centre Hospitalier Universitaire de Rouen (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Venue
- British Journal of Cancer
- Published
- 2007-03-20
- Volume
- 96
- Issue
- 8
- Pages
- 1166-1169
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2360149
- OpenAlex
- W1999250974
- Cited by
- 734
- References
- 12
- Citations by year
- 2025: 6 · 2024: 6 · 2023: 10 · 2022: 10 · 2021: 8 · 2020: 15 · 2019: 14 · 2018: 14 · 2017: 21 · 2016: 30 · 2015: 33 · 2014: 54 · 2013: 52 · 2012: 62
- FWCI
- 51.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Institut National Du Cancer
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- KRAS mutation, metastatic colorectal cancer, cetuximab, anti-EGFR therapy, predictive biomarkers, chemotherapy-refractory cancer, SNaPshot assay, mutation detection sensitivity, time to progression, clinical response
- MeSH terms
- Cetuximab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Humans, Mutation, Neoplasm Metastasis, Genes, ras, Colorectal Neoplasms, Polymerase Chain Reaction, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
